MAP2K7 and neoplasm: The antitumor activities of an estrogen receptor antagonist/degrader (fulvestrant), a RAF/MEK clamp (avutometinib), and a FAK inhibitor (VS-4718) were determined by establishing xenografts from the primary LGSOC tumor sample OVA(K)250.